Skip to main content
. 2012 Aug 24;7(8):e43314. doi: 10.1371/journal.pone.0043314

Figure 4. Plasma pharmacokinetics of BPR0L075 in CD-1 mice after administration of drug at 50 mg/kg intraperitoneally.

Figure 4

(A) LC-MS/MS analysis of BPR0L075 with chromatogram showing the retention time of internal standard [1-(1H-indol-3-ylcarbonyl)-1H-imidazole] and BPR0L075 as 2.1 and 2.8 min, respectively. (B) The plasma concentration-time curve following BPR0L075 treatment.